Cargando…
Rethinking methods used to evaluate effectiveness of therapeutics for COVID-19 and other viral respiratory illnesses
Autor principal: | Rossignol, Jean-François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756609/ https://www.ncbi.nlm.nih.gov/pubmed/35058984 http://dx.doi.org/10.2217/fvl-2021-0209 |
Ejemplares similares
-
Rethinking COVID-19 in children: Lessons learned from pediatric viral and inflammatory cardiovascular diseases
por: Barach, Paul, et al.
Publicado: (2020) -
COVID-19: A rethink of corticosteroid injection?
por: Little, Christopher P., et al.
Publicado: (2020) -
Rethinking high-risk groups in COVID-19
por: Vishnevetsky, Anastasia, et al.
Publicado: (2020) -
Mice with humanized-lungs and immune system - an idealized model for COVID-19 and other respiratory illness
por: Pujhari, Sujit, et al.
Publicado: (2020) -
Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections
por: Sies, Helmut, et al.
Publicado: (2020)